Journal
TRENDS IN BIOTECHNOLOGY
Volume 28, Issue 7, Pages 355-362Publisher
ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tibtech.2010.03.007
Keywords
-
Categories
Funding
- Ministerio de Ciencia e Innovacion [BIO2008-03233, BIO2008-00205]
- Comunidad Autonoma de Madrid [BIO-0236-2006]
- European Union
Ask authors/readers for more resources
Evolutionary pressure has selected antibodies as key immune molecules acting against foreign pathogens. The development of monoclonal antibody technology has allowed their widespread use in research, real-time diagnosis and treatment of multiple diseases, including cancer. However, compared with hematologic malignancies, solid tumors have often proven to be relatively resistant to antibody-based therapies. In an attempt to improve the tumor-targeting efficacy of antibodies, new formats with modified, multivalent properties have been generated. Initially, these formats imitated the structure of native IgG, creating mostly monospecific, bivalent antibodies. Recently, novel trivalent antibodies have been developed to maximize tumor targeting capabilities through enhanced biodistribution and functional affinity. We review recent advances in the engineering of multivalent antibodies and further discuss their promise as agents for in vivo diagnostics and therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available